prikaz prve stranice dokumenta The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis
  Download
PDF 960.39 KB
Scientific paper - Original scientific paper
The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis
Urologic Oncology, 37 (2019), 9; 578.e1-578.e10. https://doi.org/10.1016/j.urolonc.2019.03.007
Knezović Florijan, Marijana; Ozretić, Petar; Bujak, Maro; Pezzè, Laura; Ciribilli, Yari; Kaštelan, Željko; Slade, Neda; Hudolin, Tvrtko

Cite this document

Knezović Florijan, M., Ozretić, P., Bujak, M., Pezzè, L., Ciribilli, Y., Kaštelan, Ž. ... Hudolin, T. (2019). The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis. Urologic Oncology, 37. (9), 578.e1-578.e10. doi: 10.1016/j.urolonc.2019.03.007

Knezović Florijan, Marijana, et al. "The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis." Urologic Oncology, vol. 37, no. 9, 2019, pp. 578.e1-578.e10. https://doi.org/10.1016/j.urolonc.2019.03.007

Knezović Florijan, Marijana, Petar Ozretić, Maro Bujak, Laura Pezzè, Yari Ciribilli, Željko Kaštelan, Neda Slade and Tvrtko Hudolin. "The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis." Urologic Oncology 37, no. 9 (2019): 578.e1-578.e10. https://doi.org/10.1016/j.urolonc.2019.03.007

Knezović Florijan, M., et al. (2019) 'The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis', Urologic Oncology, 37(9), pp. 578.e1-578.e10. doi: 10.1016/j.urolonc.2019.03.007

Knezović Florijan M, Ozretić P, Bujak M, Pezzè L, Ciribilli Y, Kaštelan Ž, and sur.. The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis. Urologic Oncology [Internet]. 2019 September [cited 2024 May 13];37(9):578.e1-578.e10. doi: 10.1016/j.urolonc.2019.03.007

M. Knezović Florijan, et al., "The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis", Urologic Oncology, vol. 37, no. 9, pp. 578.e1-578.e10, September 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:861680. [Accessed: 13 May 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis
AuthorMarijana Knezović Florijan
AuthorPetar Ozretić
AuthorMaro Bujak
AuthorLaura Pezzè
AuthorYari Ciribilli
AuthorŽeljko Kaštelan
AuthorNeda Slade
AuthorTvrtko Hudolin
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Objectives: To analyze p53 mutations and gene expression of p53, ∆40p53, and ∆133p53 isoforms in renal cell cancer (RCC) tissues and normal adjacent tissue (NAT) and to associate them to clinical features and outcome. ----- Patients and methods: Forty-one randomly selected patients, with primary, previously untreated RCC, with complete clinicopathohistological data were analyzed. NAT samples were available for 37 cases. Expression of p53, ∆40p53 and ∆133p53 was determined using RT-qPCR. A functional yeast-based assay was performed to analyze p53 mutations. ----- Results: More than half (56.1%) of patients harbored functional p53 mutations, and they were significantly younger than those with wild type (WT) p53 (P = 0.032). Expression of p53, ∆40p53, and ∆133p53 was upregulated in mutant (MT) p53 RCC compared to WT p53 RCC tissues. However, there was no difference in expression of these isoforms between MT p53 RCC tissues and NAT. Expression of ∆133p53 was significantly downregulated in WT p53 tissues compared to NAT (P = 0.006). Patients that harbored functional p53 mutation had better overall survival (hazard ratio 4.32, 95% confidence interval 1.46-18.82, P = 0.006). Multivariate analysis demonstrated that tumor stage and p53 mutation might be used as independent prognostic marker for overall survival in RCC patients. ----- Conclusions: Our findings support the specific events in the carcinogenesis of RCC. p53 isoforms can be differentially expressed depending on p53 mutational status.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleUrologic Oncology
Numberingvol. 37, no. 9, pp. 578.e1-578.e10
p-ISSN1078-1439
DOIhttps://doi.org/10.1016/j.urolonc.2019.03.007
URN:NBNurn:nbn:hr:105:861680
Publication2019-09
Document URLhttp://doi.org/10.1016/j.urolonc.2019.03.007
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 10:41:57